GreenGate Partners is pleased to have advised High-Tech Gründerfonds (HTGF) on the sale of its portfolio company Tubulis to Gilead Sciences.

Gilead has entered into a definitive agreement to acquire Tubulis, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), for USD 3.15 billion upfront plus up to USD 1.85 billion in milestone payments. The transaction represents the highest-valued exit in HTGF’s history and the third unicorn exit in HTGF’s life sciences portfolio.

______________

 

Rechtsanwalt | Partner
Tobias Schönhaar
is a partner at GreenGate

_______________

Following completion of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with its Munich site continuing to serve as a hub for ADC innovation.

The transaction highlights the importance of long-term partnership between investors and founders in translating scientific innovation into impactful therapies and meaningful value creation.

Cookie Consent Banner von Real Cookie Banner

PE-DEALS EUROPE

PE-DEALS EUROPE provides you with a concise and well-structured monthly overview of private equity activity across numerous European countries. The comprehensive Excel database includes the latest transaction information and enables you to identify investment opportunities, market trends, and strategic developments across Europe at an early stage.

Your Benefits

  • Monthly overview of private equity transactions across Europe
  • Up-to-date information on investors, portfolio companies, buyers, sellers, and M&A advisers
  • Structured Excel database designed for efficient market research and transaction analysis
  • Reliable market intelligence backed by more than 20 years of experience and approximately 50,000 documented transactions in the DACH region
  • Access to approximately 300–350 newly recorded European private equity transactions every month for only €49 per month

More information: HERE